Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France

Emerg Infect Dis. 2021 Jan;27(1):113-121. doi: 10.3201/eid2701.203611. Epub 2020 Dec 1.

Abstract

We investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies and T-cell responses against SARS-CoV-2 and human coronavirus (HCoV) 229E and OC43 in 11 SARS-CoV-2 serodiscordant couples in Strausbourg, France, in which 1 partner had evidence of mild coronavirus disease (COVID-19) and in 10 unexposed healthy controls. Patients with confirmed COVID-19 were considered index patients and their partners close contacts. All index patients displayed positive SARS-CoV-2-specific antibody and T-cell responses that lasted up to 102 days after symptom onset. All contacts remained seronegative for SARS-CoV-2; however, 6 reported COVID-19 symptoms within a median of 7 days after their partners, and 4 of those showed a positive SARS-CoV-2-specific T-cell response against 3 or 4 SARS-CoV-2 antigens that lasted up to 93 days after symptom onset. The 11 couples and controls displayed positive T-cell responses against HCoV-229E or HCoV-OC43. These data suggest that exposure to SARS-CoV-2 can induce virus-specific T-cell responses without seroconversion.

Trial registration: ClinicalTrials.gov NCT04405726.

Keywords: COVID-19; IgA; IgG; IgM; RT-PCR; SARS-CoV-2; antibodies; coronavirus disease; coronavirus symptoms; household exposure; interferon; intrafamilial contacts; serologic testing; severe acute respiratory syndrome coronavirus 2; viral-specific T-cell response.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Viral / blood*
  • COVID-19 / blood
  • COVID-19 / epidemiology*
  • COVID-19 / transmission*
  • COVID-19 Testing
  • Case-Control Studies
  • Family*
  • Female
  • France / epidemiology
  • Humans
  • Immunity, Cellular
  • Male
  • Middle Aged
  • SARS-CoV-2 / immunology*
  • Seroconversion
  • Serologic Tests
  • T-Lymphocytes / physiology*

Substances

  • Antibodies, Viral

Associated data

  • ClinicalTrials.gov/NCT04405726